Should You Buy Eli Lilly Stock Before June 22?

Core Viewpoint - Eli Lilly is set to present new data on multiple GLP-1 drugs at the American Diabetes Association (ADA) event, which could significantly impact its stock performance and growth prospects [4][5][10] Group 1: Upcoming Events - The ADA's 85th Scientific Sessions will take place from June 20 to 23, where Eli Lilly will report on studies related to GLP-1 drugs, including tirzepatide, orforglipron, and retatrutide [4] - An investor event hosted by Eli Lilly on June 22 will discuss key presentations from the ADA Scientific Sessions [4] Group 2: Stock Performance and Market Sentiment - Eli Lilly's stock has been flat since the start of 2025, with no significant catalysts to drive its price higher, despite reaching over $900 earlier this year [6] - The stock is currently trading at more than 60 times its trailing earnings, indicating that investors expect near-perfect performance from the company [7] Group 3: Financial Performance - Over the trailing 12 months, Eli Lilly generated revenue exceeding $49 billion, with profits totaling $11.1 billion, a significant increase from less than $29 billion in revenue and $6.2 billion in profit in 2022 [8] - The growth attributed to new GLP-1 drugs has positively transformed the company's financial outlook [8] Group 4: Investment Potential - Eli Lilly is viewed as a strong business with promising growth prospects, potentially reaching a $1 trillion valuation in the coming years, representing an upside of over 45% from its current position [9] - Despite unimpressive year-to-date returns, the stock is considered to have significant room for growth, making it an attractive investment opportunity ahead of the ADA event [10]